Related Experiment Video
Updated: Jul 1, 2025
The Colon-26 Carcinoma Tumor-bearing Mouse as a Model for the Study of Cancer Cachexia
Published on: November 30, 2016
[The Second Web Questionnaire Survey on Cancer Cachexia Japanese Evidence for Patients Of Cancer CachexiaⅡ
Maimi Kiguchi1, Satomi Kanemata, Koji Machii
1Medical Affairs, Ono Pharmaceutical Co., Ltd.
Abstract:
In 2019, the Cancer Cachexia Web Questionnaire Survey(J-EPOCC), conducted among cancer patients, their families and healthcare professionals in Japan showed that nearly half of patients who had experienced appetite loss or weight loss during cancer treatment had not consulted with healthcare professionals about their symptoms, and it meant that patients missed the opportunity to receive medical intervention. Since anamorelin was approved in 2021 fo"r Cancer cachexia in non- small cell lung cancer, gastric cancer, pancreatic cancer and colorectal cancer", the treatment environment for cancer cachexia has greatly changed. Thus, the second Web Questionnaire Survey(J-EPOCCⅡ)was conducted in June 2022 to investigate changes in the problem awareness of cancer cachexia, especially appetite loss and weight loss, among patients and their family and healthcare professionals. The results showed that there was no apparent change in awareness of appetite loss and weight loss, suggesting many patients may miss treatment opportunities. Further disease awareness is required among patients and their families to enhance the understanding of the significance of therapeutic interventions for appetite loss or weight loss, and to call their attention for early detection and treatment.
Insights
Cancer cachexia awareness remains low, with many patients not seeking medical help for appetite or weight loss. Increased patient and family education is crucial for early detection and treatment of cancer cachexia.
Area of Science:
- Oncology
- Patient Care
- Health Services Research
Context:
- Cancer cachexia significantly impacts patient quality of life and treatment outcomes.
- The landscape of cancer cachexia treatment evolved with the 2021 approval of anamorelin.
- Previous surveys indicated a gap in patient-provider communication regarding cachexia symptoms.
Purpose:
- To assess changes in awareness of cancer cachexia, particularly appetite and weight loss, among patients, families, and healthcare professionals in Japan.
- To evaluate the impact of new therapeutic options on patient and professional understanding of cancer cachexia.
- To identify persistent barriers to seeking medical intervention for cancer cachexia symptoms.
Summary:
- The second Japan Epidemiology of Cancer Cachexia (J-EPOCC II) survey revealed no significant improvement in awareness of appetite and weight loss associated with cancer cachexia since 2019.
- A substantial number of cancer patients still do not consult healthcare professionals about these critical symptoms, potentially missing timely treatment opportunities.
- Despite advancements in cancer cachexia treatment, patient and family understanding of the condition's significance and available interventions remains insufficient.
Impact:
- Highlights the urgent need for enhanced disease awareness and education for cancer patients and their families regarding appetite and weight loss.
- Underscores the importance of early detection and intervention for cancer cachexia to improve patient outcomes.
- Suggests a need for healthcare systems to proactively address patient-reported symptoms of appetite and weight loss in cancer care.
Related Concept Videos
01:21Cancer Survival Analysis
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...